Literature DB >> 19041067

Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation: a single-institution, nested case-controlled study.

Coralia N Mihu1, Jenifer Schaub, Sandra Kesh, Ann Jakubowski, Kent Sepkowitz, Eric G Pamer, Genovefa A Papanicolaou.   

Abstract

We report on the incidence, risk factors, and outcome of late Staphylococcus aureus bacteremia (SAB) in a cohort of 709 adult and pediatric patients at Memorial Sloan-Kettering Cancer Center between September 1999 and December 2006. The SAB cases were identified by prospective surveillance and examination of a computerized database. Late SAB was defined as SAB occurring > 50 days post-hematopoietic stem cell transplantation (HSCT). A nested case-controlled study was conducted to identify predictors of late SAB. The incidence of late SAB was 6/100,000 patient-days. The median time from stem cell infusion to incident blood culture was 137 days (range, 55 to 581 days). Eighty-four percent of the cases were community acquired; 40% involved a focal infection. Bacteremia was persistent (>3 days) despite removal of endovascular access in > 50% of cases. Risk factors for late SAB were acute graft-versus-host disease (aGVHD) flare, acute or chronic skin GVHD (cGVHD), corticosteroid use, liver dysfunction, and prolonged hospital length of stay (LOS) post-HSCT. In multivariate models, skin GVHD (P = .002) and LOS (P = .02) remained significant. The median survival post-SAB was 135 days (range, 1 to 1765 days). Late SAB occurred mainly in the setting of GVHD or corticosteroid therapy. Clinical manifestations were highly variable. Multiple comorbidities, indicated by organ dysfunction and hospitalization, likely contributed to persistence and increased morbidity and mortality. We recommend a high index of suspicion and empiric antistaphylococcal treatment pending culture results in high-risk patients undergoing HSCT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041067      PMCID: PMC6000823          DOI: 10.1016/j.bbmt.2008.09.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  11 in total

1.  Aerobic bacterial and fungal infections in peripheral blood stem cell transplants.

Authors:  G Aksu; M Z Ruhi; H Akan; S Bengisun; C Ustün; O Arslan; H Ozenci
Journal:  Bone Marrow Transplant       Date:  2001-01       Impact factor: 5.483

Review 2.  Guidelines for the management of intravascular catheter-related infections.

Authors:  L A Mermel; B M Farr; R J Sherertz; I I Raad; N O'Grady; J S Harris; D E Craven
Journal:  Clin Infect Dis       Date:  2001-04-03       Impact factor: 9.079

3.  Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients.

Authors:  B A Collin; H L Leather; J R Wingard; R Ramphal
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

4.  Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak.

Authors:  B E Shaw; T Boswell; J L Byrne; C Yates; N H Russell
Journal:  Bone Marrow Transplant       Date:  2007-03-26       Impact factor: 5.483

5.  Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy.

Authors:  A K Gopal; V G Fowler; M Shah; D Gesty-Palmer; K A Marr; R S McClelland; L K Kong; G S Gottlieb; K Lanclos; J Li; D J Sexton; G R Corey
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

6.  Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients.

Authors:  N G Almyroudis; A Fuller; A Jakubowski; K Sepkowitz; D Jaffe; T N Small; T E Kiehn; E Pamer; G A Papanicolaou
Journal:  Transpl Infect Dis       Date:  2005-03       Impact factor: 2.228

7.  New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service.

Authors:  D T Durack; A S Lukes; D K Bright
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

8.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.

Authors:  Sara E Cosgrove; George Sakoulas; Eli N Perencevich; Mitchell J Schwaber; Adolf W Karchmer; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2002-12-13       Impact factor: 9.079

Review 9.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

10.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

View more
  8 in total

1.  Evaluation of routine pretransplantation screening for methicillin-resistant Staphylococcus aureus in hematopoietic cell transplant recipients.

Authors:  Arianna Miles-Jay; Sara Podczervinski; Zach J Stednick; Steven A Pergam
Journal:  Am J Infect Control       Date:  2015-01       Impact factor: 2.918

2.  Staphylococcus aureus infections among children receiving a solid organ transplant: clinical features, epidemiology, and antimicrobial susceptibility.

Authors:  J C McNeil; F M Munoz; K G Hultén; E O Mason; S L Kaplan
Journal:  Transpl Infect Dis       Date:  2015-01-09       Impact factor: 2.228

Review 3.  Innate Immunity to Staphylococcus aureus: Evolving Paradigms in Soft Tissue and Invasive Infections.

Authors:  Stephanie L Brandt; Nicole E Putnam; James E Cassat; C Henrique Serezani
Journal:  J Immunol       Date:  2018-06-15       Impact factor: 5.422

4.  Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation.

Authors:  Michael Slade; Scott Goldsmith; Rizwan Romee; John F DiPersio; Erik R Dubberke; Peter Westervelt; Geoffrey L Uy; Steven J Lawrence
Journal:  Transpl Infect Dis       Date:  2016-12-28       Impact factor: 2.228

5.  Plasma Cell-Free DNA Next-Generation Sequencing to Diagnose and Monitor Infections in Allogeneic Hematopoietic Stem Cell Transplant Patients.

Authors:  Monica Fung; Simona Zompi; Hon Seng; Desiree Hollemon; Adama Parham; David K Hong; Sivan Bercovici; Estelle Dolan; Kathy Lien; Justin Teraoka; Aaron C Logan; Peter Chin-Hong
Journal:  Open Forum Infect Dis       Date:  2018-11-16       Impact factor: 3.835

6.  Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation.

Authors:  Celalettin Ustun; Jo-Anne H Young; Genovefa A Papanicolaou; Soyoung Kim; Kwang Woo Ahn; Min Chen; Hisham Abdel-Azim; Mahmoud Aljurf; Amer Beitinjaneh; Valerie Brown; Jan Cerny; Saurabh Chhabra; Mohamed A Kharfan-Dabaja; Parastoo B Dahi; Andrew Daly; Christopher E Dandoy; Christopher C Dvorak; Cesar O Freytes; Shahrukh Hashmi; Hillard Lazarus; Per Ljungman; Taiga Nishihori; Kristin Page; Sai R K Pingali; Ayman Saad; Bipin N Savani; Daniel Weisdorf; Kirsten Williams; Baldeep Wirk; Jeffery J Auletta; Caroline A Lindemans; Krishna Komanduri; Marcie Riches
Journal:  Bone Marrow Transplant       Date:  2018-12-13       Impact factor: 5.483

7.  Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.

Authors:  Agnieszka Sobkowiak-Sobierajska; Caroline Lindemans; Tomas Sykora; Jacek Wachowiak; Jean-Hugues Dalle; Halvard Bonig; Andrew Gennery; Anita Lawitschka
Journal:  Front Pediatr       Date:  2022-02-18       Impact factor: 3.418

8.  Prevalence of infectious multi-drug resistant bacteria isolated from immunocompromised patients in Tunisia.

Authors:  Arij Mechergui; Wafa Achour; Sondos Mathlouthi; Assia Ben Hassen
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.